Pyxis Oncology, Inc. (PYXS) Insider Ownership

Historic Insider Ownership Trends

As of March 23, 2026, Pyxis Oncology's top three insider holders are Lara Sullivan (President And Ceo, 2.40Mn shares), Pamela Ann Connealy (Cfo Coo, 1.20Mn shares), Asset Management, Lp Cormorant (Other, 1.12Mn shares).

Top Direct Holders

Insider ownership data is derived from the last 60 months of Form 4 SEC filings.
Holder Position Shares (Direct) Shares (Indirect) Report Date
Lara Sullivan President And Ceo 2,403,882 0 18 Sep, 2023
Pamela Ann Connealy Cfo Coo 0 1,199,143 27 Nov, 2024
Asset Management, Lp Cormorant 0 1,118,854 15 Oct, 2021
Pamela Ann Connealy Cfo Coo 1,110,293 0 28 Mar, 2024
Jay Feingold Chief Medical Officer 730,345 0 28 Mar, 2023
Jitendra Wadhane Svp, Chief Accounting Officer 398,421 0 28 Mar, 2024
Darren S Cline 251,405 0 28 Mar, 2024
Thomas Civik 206,186 0 28 Mar, 2023
Rachel Humphrey 96,805 0 28 Mar, 2024
Mark Chin 66,831 0 04 Apr, 2022
Jakob Dupont 38,741 0 28 Mar, 2024
Thomas Civik 0 15,700 19 Nov, 2021
Santhosh Palani 6,000 0 07 Jun, 2024

* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.

Recent Insider Transactions

Detailed insider trading activity based on Form 4 SEC filings.
Download Data
Transaction Date Insider Name Security Class Transaction Type Shares Traded Price Shares Remaining Ownership Code
03 Feb, 2026 Thomas Civik Stock Option (Right to Buy) A 690,131 $0.00 690,131 D A
31 Mar, 2025 Santhosh Palani Stock Option (Right to Buy) A 36,979 $0.98 36,979 D A
31 Mar, 2025 Jakob Dupont Stock Option (Right to Buy) A 36,979 $0.98 36,979 D A
31 Mar, 2025 Rachel Humphrey Stock Option (Right to Buy) A 36,979 $0.98 36,979 D A
31 Mar, 2025 Pamela Ann Connealy Stock Option (Right to Buy) A 414,163 $0.98 414,163 D A
31 Mar, 2025 Jitendra Wadhane Stock Option (Right to Buy) A 263,782 $0.98 263,782 D A
31 Mar, 2025 Lara Sullivan Stock Option (Right to Buy) A 918,308 $0.98 918,308 D A
31 Mar, 2025 Thomas Civik Stock Option (Right to Buy) A 36,979 $0.98 36,979 D A
31 Mar, 2025 Darren S Cline Stock Option (Right to Buy) A 36,979 $0.98 36,979 D A
23 Dec, 2024 Pamela Ann Connealy Stock Option (Right to Buy) A 310,000 $0.00 310,000 D A
23 Dec, 2024 Jitendra Wadhane Stock Option (Right to Buy) A 150,000 $0.00 150,000 D A
23 Dec, 2024 Lara Sullivan Stock Option (Right to Buy) A 1,135,000 $0.00 1,135,000 D A
26 Nov, 2024 Pamela Ann Connealy Common Stock A 5,450 $2.00 1,115,743 I P
26 Nov, 2024 Pamela Ann Connealy Common Stock A 83,400 $1.96 1,199,143 I P
07 Jun, 2024 Santhosh Palani Common Stock A 6,000 $0.00 6,000 D A
26 Mar, 2024 Pamela Ann Connealy Common Stock A 328,710 $0.00 1,110,293 D A
26 Mar, 2024 Darren S Cline Common Stock A 35,219 $0.00 251,405 D A
26 Mar, 2024 Lara Sullivan Stock Option (Right to Buy) A 1,071,242 $3.83 1,071,242 D A
26 Mar, 2024 Thomas Civik Stock Option (Right to Buy) A 44,024 $3.83 44,024 D A
26 Mar, 2024 Jakob Dupont Common Stock A 38,741 $0.00 38,741 D A